Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?

The past decade in hepatology has witnessed great victories in the treatment of viral hepatitis and resounding failures in nonalcoholic steatohepatitis (NASH). This is sobering, given the global shift in the burden of disease from viral hepatitis toward NASH. Key therapeutic casualties in NASH have included simtuzumab,1Harrison S.A. Abdelmalek M.F. Caldwell S. et al.Simtuzumab is ineffective for patients with bridging fibrosis or compensated...